证券代码：301075 证券简称：多瑞医药 公告编号：2025-072 西藏多瑞医药股份有限公司 关于使用暂时闲置募集资金进行现金管理到期赎回并继续进行现金 管理的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 西藏多瑞医药股份有限公司（以下简称"公司"）于 2024 年 10 月 23 日分别召开了第二届董事会第十六次会议、第二届监事会第十五 次会议审议通过了《关于使用部分暂时闲置募集资金进行现金管理的 议案》，同意公司使用最高不超过人民币 32,000 万元（含本数）的闲 置募集资金进行现金管理，用于购买安全性高、流动性好、不影响公 司正常经营的理财产品。使用期限为自公司董事会审议通过之日起 12 个月内，在上述使用期限及额度范围内，资金可循环滚动使用。 在额度范围内授权公司法定代表人及其授权人士签署相关合同文件， 授权期限自董事会审议通过之日起 12 个月内有效。该事项已经公司 董事会、监事会审议通过，保荐机构中信证券股份有限公司对公司使 用部分暂时闲置募集资金进行现金管理出具了明确的核查意见。具体 内容详见于巨潮资讯网（www.cninfo. ...

Group 1 - The core viewpoint of the news is that Duorui Pharmaceutical's stock performance and financial metrics indicate a challenging period, with significant declines in revenue and net profit [1][2]. - On September 15, Duorui Pharmaceutical's stock fell by 0.85%, with a trading volume of 118 million yuan. The net financing purchase on that day was 4.64 million yuan, with a total financing and securities balance of 101 million yuan [1]. - The financing balance of Duorui Pharmaceutical is 101 million yuan, accounting for 2.91% of its market capitalization, which is above the 80th percentile of the past year, indicating a high level of financing activity [1]. Group 2 - As of June 30, the number of shareholders of Duorui Pharmaceutical increased by 2.96% to 7,627, while the average circulating shares per person decreased by 2.87% to 10,489 shares [2]. - For the first half of 2025, Duorui Pharmaceutical reported a revenue of 107 million yuan, a year-on-year decrease of 29.13%, and a net profit attributable to shareholders of -42.5 million yuan, representing a significant decline of 1197.26% [2]. - Since its A-share listing, Duorui Pharmaceutical has distributed a total of 59.87 million yuan in dividends, with 9.87 million yuan distributed over the past three years [2].

证券代码：301075 证券简称：多瑞医药 公告编号：2025-071 | 序 | 购买 | 受托方名称 | 产品名称 | | 金额 | 产品 | 产品起息 | 产品 | 预期年化 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 号 | 主体 | | | | （万元） | 类型 | 日 | 到期日 | 收益率 | | 1 | 湖北多瑞药 | 中信证券股 | 安鑫增益系列 | 252 | 2,000 | 固定收益凭 | 2025/9/9 | 2025/9/23 | 1.5900% | | | 业有限公司 | 份有限公司 | 期收益凭证 | | | 证 | | | | 一、 使用部分闲置募集资金进行现金管理到期赎回的情况 关于使用暂时闲置募集资金进行现金管理到期赎回并继续进行现金 管理的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 西藏多瑞医药股份有限公司（以下简称"公司"）于 2024 年 10 月 23 日分别召开了第二届董事会第十六次会议、第二届监事会第十五 次会 ...

（编辑 任世碧） 证券日报网讯 9月3日晚间，多瑞医药发布公告称，截至本公告日，公司对外担保额度为56，500万元， 实际发生的对外担保余额23，230万元，占公司最近一期经审计净资产的比例为34.33%；公司对合并报 表外单位实际发生的担保余额为0.00万元；公司无逾期担保贷款，无涉及诉讼的担保金额及因担保而被 判决败诉而应承担的损失金额。 ...

证券代码：301075 证券简称：多瑞医药 公告编号：2025-070 西藏多瑞医药股份有限公司 关于向控股子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 一、担保情况概述 西藏多瑞医药股份有限公司（以下简称"公司"）于 2025 年 3 月 6 日召开第二届董事会第十八次会议和第二届监事会第十七次会议，审 议通过了《关于向控股子公司提供担保的议案》，同意公司为控股子 公司湖北鑫承达化工有限公司（以下简称"鑫承达"）向银行申请综合 授信提供合计不超过 1,500 万元人民币的连带责任保证担保，鑫承达 少数股东武汉市盛祥化工有限公司、武汉金盛兴自控工程有限公司按 出资比例提供同等担保或者反担保。具体内容详见公司同日在巨潮资 讯网（www.cninfo.com.cn）披露的相关公告。 二、对外担保进展情况 近日，公司与中国工商银行股份有限公司宜城支行（以下简称"工 商银行宜城支行"）签署了《最高额保证合同》，公司为控股子公司鑫 承达向工商银行宜城支行申请人民币 530 万元的综合授信额度提供 连带责任保证担保，保证期间以公司与工商银行宜城 ...

Group 1 - Kangchen Pharmaceutical and Puris reached the daily limit increase, while Duri Pharmaceutical rose over 10% [1] - Huahai Pharmaceutical, Haoyuan Pharmaceutical, Jimin Health, Warner Pharmaceuticals, and Medisyn also experienced gains [1]

Group 1 - The A-share chemical pharmaceutical sector experienced a rebound, with notable stock performances [1] - Sunflower stock surged by 20% and hit the daily limit, indicating strong market interest [1] - Other companies such as Duoyi Pharmaceutical and Huahai Pharmaceutical saw increases of over 13% and 9% respectively, reflecting a positive trend in the sector [1]

Core Viewpoint - The innovative pharmaceutical stocks experienced a significant rebound, with Huahai Pharmaceutical and Kangchen Pharmaceutical both hitting the daily limit up, indicating strong market interest and investor confidence in the sector [1] Industry Summary - The National Medical Products Administration of China reported that the country's pharmaceutical industry ranks second globally, with approximately 30% of the world's innovative drugs currently under research [1] - Since the beginning of the 14th Five-Year Plan, a total of 387 pediatric drugs and 147 rare disease drugs have been approved for market, effectively addressing the medication needs of key populations [1] Company Summary - Huahai Pharmaceutical and Kangchen Pharmaceutical both reached the daily limit up, reflecting positive market sentiment towards their stock performance [1] - Other companies such as Puris, Duolai Pharmaceutical, Haoyuan Pharmaceutical, Huana Pharmaceutical, Medisi, Lifang Pharmaceutical, and Guangshengtang also saw stock increases, with some rising over 5% [1]

Core Viewpoint - Duori Pharmaceutical (301075.SZ) reported a significant decline in revenue and net profit for the first half of 2025, indicating challenges in its core product market and the need for strategic adjustments to improve financial performance [1][3]. Financial Performance - The company recorded a revenue of 107 million yuan, a year-on-year decrease of 29.13% [1]. - The net profit attributable to the parent company was -42.5 million yuan [1]. Product and Market Analysis - The primary revenue source for the company is the sodium acetate injection, which has maintained a leading market share [3]. - The product has been included in the 10th batch of the national drug centralized procurement list, which has set a foundation for future sales but has led to profit compression due to a "price-for-volume" strategy [3]. Strategic Initiatives - To mitigate the impact of reliance on a single product, the company is accelerating its business layout in raw materials and new formulations through acquisitions [3]. - The acquisitions of Xinchengda and Sichuan Duori have initiated an integrated development model for raw materials and formulations [3]. - New products such as amisulpride injection, sodium bicarbonate injection, and levetiracetam oral solution are in the review stage, which will enhance the product pipeline upon approval [3]. High-End Market Positioning - The company is entering the high-end peptide raw material market, aligning with policy directions and aiming for performance growth [3]. - Peptide drugs, which are complex to synthesize and have historically been dominated by Western companies, present a new opportunity for domestic firms [3]. Future Outlook - The company anticipates that the release of national and local policy benefits, along with the maturation of new business areas, will gradually improve its operational status and achieve high-quality development [4].

Group 1 - The core viewpoint of the article highlights the announcement by Duori Pharmaceutical regarding its board meeting and the composition of its revenue for the year 2024 [1] - Duori Pharmaceutical's revenue composition for 2024 indicates that the pharmaceutical manufacturing sector accounts for 57.85% while other sectors contribute 42.15% [1] - As of the report, Duori Pharmaceutical has a market capitalization of 3.3 billion yuan [1] Group 2 - The article also mentions the booming pet industry, valued at 300 billion yuan, and the positive market response from listed companies in this sector [1]